Optimal pharmacotherapy to combat the atherogenic lipid triad

Current Opinion in Cardiology

Volumn 26, Issue 5, 2011, Pages 403-411

  Chapman, M John ^a,b   Redfern, Jan S ^c   McGovern, Mark E ^d   Giral, Philippe ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Redfern Strategic Medical Communications Inc   (United States)

^d NONE   (United States)

Author keywords

atherogenic dyslipidemia; cholesterol; fibrates; niacin; statins; triglyceride

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; BILE ACID SEQUESTRANT; CIPROFIBRATE; CYCLOSPORIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; G PROTEIN COUPLED RECEPTOR; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT PLUS NICOTINIC ACID; LOVASTATIN PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MK 0354; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; WARFARIN;

ATHEROGENESIS; ATHEROGENIC DYSLIPIDEMIA; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLUSHING; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIVER TOXICITY; MORTALITY; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; MYALGIA; MYOPATHY; MYOSITIS; NONHUMAN; PATIENT COMPLIANCE; PLEIOTROPY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; STROKE; SUDDEN DEATH; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

EID: 80051799417     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32834965e9     Document Type: Review

References (53)

1. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302:1993-2000.
2. Chapman MJ, Redfern JS, McGovern ME, et al. Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 2010; 126:314-345. This article provides a comprehensive and critical review of 25 years of research on the pharmacology, lipid-modifying and antiatherosclerosis effects, and outcomes benefits of niacin and fibrates.
3. Kirk EP, Klein S. Pathogenesis and pathophysiology of the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 2009; 11:761-765.
4. Robins SJ, Lyass A, Zachariah JP, et al. Insulin resistance and the relationship of a dyslipidemia to coronary heart disease: The Framingham Heart Study. Arterioscler Thromb Vasc Biol 2011; 31:1208-1214.
5. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005; 366:1849-1861.
6. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563-1574. This article presents the results of the most recent outcomes study of fibrate therapy and suggests that routine use of fenofibrate and simvastatin to reduce cardiovascular risk is not warranted for most high-risk patients with type 2 diabetes.
7. Taskinen MR, Sullivan DR, Ehnholm C, et al. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate. Arterioscler Thromb Vasc Biol 2009; 29:950-955.
8. Chapman MJ, Le Goff W, Guerin M, et al. Cholesteryl ester transfer protein: At the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. EurHeart J 2009; 31:149-164.
9. Fazio S, Linton MF. The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy. Curr Atheroscler Rep 2004; 6:148-157.
10. Enger C, Gately R, Ming EE, et al. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. Am J Cardiol 2010; 106:1594-1601. This retrospective cohort study of claims data from a US managed care plan analyzes the safety profile of fibrate and statin therapy.
11. Loomba RS, Arora R. Prevention of cardiovascular disease utilizing fibrates: A pooled meta-analysis. Am J Ther 2010; 17:e182-e188. This meta-analysis of randomized controlled trials examines the effect of fibrates on cardiovascular outcomes.
12. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis. Lancet 2010; 375:1875-1884. This meta-analysis of randomized controlled trials examines the effect of fibrates on cardiovascular outcomes.
13. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260:641-651.
14. BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102:21-27.
15. Scott R, O'Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9795 individuals with type 2 diabetes and various components of the metabolic syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009; 32:493-498.
16. Barter PJ, Rye KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol 2008; 28:39-46.
17. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): A randomised controlled trial. Lancet 2007; 370:1687-1697.
18. European Medicines Agency Committee for Medicinal Products for Human Use: Questions and answers on the review of medicines containing fibrates outcome of a procedure under article 31 of directive 2001/83/EC as amended. http://www.ema.europa.eu/docs/en-GB/document-library/Refer rals-document/ Fibrates-31/WC500098373.pdf. [Accessed 17 February 2011]
19. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007; 99:22C-31C.
20. Menon RM, Gonzalez MA, Adams MH, et al. Effect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolites. J Clin Pharmacol 2007; 47:681-688.
21. MacLean A, McKenney JM, Scott R, et al. Efficacy and safety of extendedrelease niacin/laropiprant in patients with type 2 diabetes mellitus. Br J Cardiol 2011; 18:37-45. This clinical trial in patients with type 2 diabetes shows that extended-release niacin plus laropiprant produces marked and durable improvements in lipids/ lipoproteins and is generally well tolerated.
22. Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008; 62:1959-1970.
23. Shah S, Ceska R, Gil-Extremera B, et al. Efficacy and safety of extendedrelease niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2010; 64:727-738. This clinical trial shows that adding extended-release niacin/laropiprant to ongoing statin therapy produces superior improvements in lipids/lipoproteins compared with doubling the statin dose.
24. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J 2010; 31:2844-2853. This article, which reviewed the relationship between elevated Lp(a) levels and cardiovascular disease/coronary heart disease, recommends screening for Lp(a) in intermediate or high cardiovascular risk patients and suggests niacin therapy as a possible therapeutic strategy.
25. Gille A, Bodor ET, Ahmed K, et al. Nicotinic acid: Pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol 2008; 48:79-106.
26. Lai E, Waters MG, Tata JR, et al. Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans. J Clin Lipidol 2008; 2:375-383.
27. Kamanna VS, Vo A, Kashyap ML. Nicotinic acid: Recent developments. Curr Opin Cardiol 2008; 23:393-398.
28. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol 2008; 101:20B-26B.
29. Ganji SH,Qin S, Zhang L, et al. Niacin inhibits vascular oxidative stress, redoxsensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009; 202:68-75.
30. Thoenes M, Oguchi A, Nagamia S, et al. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int J Clin Pract 2007; 61:1942-1948.
31. Florentin M, Liberopoulos EN, Kei A, et al. Pleiotropic effects of nicotinic acid: Beyond high density lipoprotein cholesterol elevation. Curr Vasc Pharmacol 2011. [Epub ahead of print] This article reviews the antithrombotic, anti-inflammatory, and antioxidant effects of niacin and their possible contribution to niacin's observed cardiovascular benefits.
32. Lukasova M, Malaval C, Gille A, et al. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest 2011; 121:1163-1173.
33. Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acidinduced flushing in patients with dyslipidemia. Am J Cardiol 2008; 101:625-630.
34. Dunbar RL, Gelfand JM. Seeing red: Flushing out instigators of niacinassociated skin toxicity. J Clin Invest 2010; 120:2651-2655.
35. Hanson J, Gille A, Zwykiel S, et al. Nicotinic acid- and monomethyl fumarateinduced flushing involves GPR109A expressed by keratinocytes and COX-2- dependent prostanoid formation in mice. J Clin Invest 2010; 120:2910-2919.
36. Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc 2008; 83:470-478.
37. Fazio S, Guyton JR, Polis AB, et al. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. Am J Cardiol 2010; 105:487-494.
38. Lee JM, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: A randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009; 54:1787-1794.
39. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361:2113-2122.
40. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): Final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010; 55:2721-2726. This article presents the final results of ARBITER 6-HALTS trial and shows that niacin is superior to ezetimibe in regressing carotid intima-media thickness in patients receiving statins.
41. Blumenthal RS, Michos ED. The HALTS trial-halting atherosclerosis or halted too early? N Engl J Med 2009; 361:2178-2180.
42. Kastelein JJ, Bots ML. Statin therapy with ezetimibe or niacin in high-risk patients. N Engl J Med 2009; 361:2180-2183.
43. Sibley CT, Gottlieb I, Cox C, et al. Abstract 685: Comparative effect of statins vs niacin on MRI measured regression of carotid atherosclerosis in a randomized clinical trial: The NIA Plaque Study. Circulation 2009; 120:S376.
44. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010; 210:353-361. This meta-analysis of randomized controlled trials reveals benefits of niacin (alone or in combination) on all cardiovascular events and atherosclerosis progression.
45. Brown BG, Zhao XQ, Cheung MC. Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence. J Clin Lipidol 2007; 1:88-94.
46. Brown BG, Zhao XQ. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol 2008; 101:58B-62B.
47. AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: Baseline characteristics of study participants. The atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides: Impact on global health outcomes (AIM-HIGH) trial. Am Heart J 2011; 161:538-543. This article describes the baseline characteristics of patients enrolled in the AIMHIGH trial, a key ongoing study designed to assess whether niacin superimposed on statin therapy reduces residual CV risk beyond statin alone.
48. AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: Rationale and study design. The atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides: Impact on global health outcomes (AIM-HIGH). Am Heart J 2011; 161:471-477. This article describes the rationale and study design of the AIM-HIGH trial, a key ongoing study designed to assess whether niacin superimposed on statin therapy reduces residual CV risk beyond statin alone.
49. Hubacek JA, Adamkova V, Vrablik M, et al. Apolipoprotein A5 in health and disease. Physiol Res 2009; 58 (Suppl 2):S101-S109.
50. Rosenson RS. A treasure of pharmacogenomic insights into postprandial lipoproteinemia and therapeutic responses to fibrate therapy: Lessons from GOLDN. Curr Atheroscler Rep 2009; 11:161-164.
51. Couvert P, Giral P, Dejager S, et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 2008; 9:1217-1227.
52. Couvert P, Chapman MJ, Carrie A. Impact of genetic variation in the SLCO1B1 gene on statin efficacy in low-density lipoprotein cholesterollowering therapy. Pharmacogenomics 2011; 12:137-139.
53. Pan J, Shilian P, Ishida B, et al. Effect of niacin on prebeta-1 high-density lipoprotein levels in diabetes. Metabolism 2011; 60:292-297.